Cara Therapeutics Faces Delisting Concerns
Ticker: TVRD · Form: 8-K · Filed: Aug 1, 2024 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Cara Therapeutics, Inc. (TVRD) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, compliance
Related Tickers: CARA
TL;DR
Cara Therapeutics might get delisted from Nasdaq.
AI Summary
Cara Therapeutics, Inc. filed an 8-K on August 1, 2024, reporting a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates potential issues with meeting Nasdaq's continued listing requirements as of July 31, 2024.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the company's stock being removed from Nasdaq, impacting investor confidence and liquidity.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on a major exchange, posing a significant risk to its operations and stock value.
Key Players & Entities
- Cara Therapeutics, Inc. (company) — Registrant
- Nasdaq (company) — Stock Exchange
FAQ
What specific listing rule or standard is Cara Therapeutics failing to meet?
The filing does not specify the exact rule or standard that Cara Therapeutics is failing to meet, only that it has received a notice regarding failure to satisfy a continued listing rule or standard.
What is the date of the event triggering this 8-K filing?
The earliest event reported is July 31, 2024.
What is Cara Therapeutics' principal executive office address?
The address is 400 Atlantic Street, Suite 500, Stamford, Connecticut 06901.
What is Cara Therapeutics' Commission File Number?
The Commission File Number for Cara Therapeutics is 001-36279.
What is the filing date of this 8-K report?
This 8-K report was filed as of August 1, 2024.
Filing Stats: 693 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2024-08-01 16:15:55
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Marke
- $1.00 — the Company's common stock is at least $1.00 per share for a minimum of 10 consecuti
Filing Documents
- tm2420653d1_8k.htm (8-K) — 25KB
- 0001104659-24-084911.txt ( ) — 194KB
- cara-20240731.xsd (EX-101.SCH) — 3KB
- cara-20240731_lab.xml (EX-101.LAB) — 33KB
- cara-20240731_pre.xml (EX-101.PRE) — 22KB
- tm2420653d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARA THERAPEUTICS, INC. By: /s/ RYAN MAYNARD Ryan Maynard Chief Financial Officer Date: August 1, 2024